Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25

Immuneering Corporation (NASDAQ:IMRX) has been given an average rating of “Moderate Buy” by the five research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $13.25.

A number of research firms recently issued reports on IMRX. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Immuneering in a report on Wednesday, June 18th. Oppenheimer lowered their target price on Immuneering from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, Mizuho raised their price objective on Immuneering from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 18th.

Immuneering Price Performance

Shares of IMRX opened at $4.13 on Wednesday. The firm has a market capitalization of $148.64 million, a P/E ratio of -2.11 and a beta of 0.38. Immuneering has a one year low of $1.00 and a one year high of $4.60. The business has a fifty day moving average of $2.58 and a 200 day moving average of $1.98.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.01). Analysts expect that Immuneering will post -1.86 EPS for the current fiscal year.

Insider Activity

In related news, Director Thomas J. Schall bought 40,485 shares of the stock in a transaction dated Tuesday, June 17th. The shares were purchased at an average price of $2.21 per share, with a total value of $89,471.85. Following the completion of the acquisition, the director owned 43,385 shares of the company’s stock, valued at $95,880.85. This represents a 1,396.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin J. Zeskind purchased 21,000 shares of Immuneering stock in a transaction on Wednesday, June 18th. The stock was bought at an average price of $2.39 per share, for a total transaction of $50,190.00. Following the completion of the acquisition, the chief executive officer owned 2,302,852 shares in the company, valued at $5,503,816.28. The trade was a 0.92% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 127,507 shares of company stock worth $334,318 over the last ninety days. Corporate insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMRX. Flower City Capital purchased a new position in shares of Immuneering in the second quarter valued at $108,000. Jane Street Group LLC bought a new position in shares of Immuneering in the 1st quarter valued at about $32,000. HighTower Advisors LLC increased its stake in Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock worth $128,000 after acquiring an additional 12,600 shares during the last quarter. Two Sigma Investments LP raised its position in Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after purchasing an additional 10,126 shares during the period. Finally, Tang Capital Management LLC bought a new stake in shares of Immuneering in the 4th quarter valued at approximately $27,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.